Zymeworks Announces Participation in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Zymeworks (ZYME) PT Raised to $26 at Leerink Partners
November 21, 2024 9:22 AM ESTLeerink Partners analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $26.00 (from $25.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: The FDA granted accelerated approval to Ziihera (zanidatamab) in pre-treated HER2+ (IHC3+) biliary tract cancer (BTC) patients ahead of its PDUFA date of Nov. 29, 2024. This approval was widely anticipated. As a reminder, ZYME previously outlicensed Ziihera to partner Jazz Pharmaceuticals (JAZZ, Goodman, OP) in 2022 and will now receive a $25mn regulatory milestone from JAZZ. ZYME remains eligible... More
